Skip to content
To the full analysis

Enanta Pharmaceuticals stock: balance sheet and debt

ENTA
$11.20Closing price of 12 Nov 2026MEQIRI Score 27 out of 100

Enanta Pharmaceuticals has a debt to equity ratio of 3.11.

Daily figure as of 13 Nov 2026

Debt / Equity
3.11
Interest coverage
−9.9x
Current ratio
4.21
Cash & equivalents
$188.86M
Total assets
$280.73M
Equity ratio
23.1%
Goodwill
not reported separately
Net debt
$12.19M

Total assets and equity ratio

How large the balance sheet of Enanta Pharmaceuticals, Inc. is, how much of it is equity and how much is goodwill from acquisitions.

Equity ratio

Figures as a table
YearTotal assetsGoodwill and intangible assetsof which goodwillEquity ratioNet debt
2010no datano datano datano data$0
2011$26.1Mnot reported separatelynot reported separately−505.7%−$23.33M
2012$52.16Mnot reported separatelynot reported separately84.2%−$43.76M
2013$116.97Mnot reported separatelynot reported separately94.4%−$101.48M
2014$155.42Mnot reported separatelynot reported separately95.6%−$90.56M
2015$246.01Mnot reported separatelynot reported separately96.0%−$144.61M
2016$281.28Mnot reported separatelynot reported separately96.0%−$209.55M
2017$326.64Mnot reported separatelynot reported separately92.4%−$223.21M
2018$414.23Mnot reported separatelynot reported separately95.0%−$308.44M
2019$489.83Mnot reported separatelynot reported separately94.4%−$335.04M
2020$490.79Mnot reported separatelynot reported separately92.8%−$377.07M
2021$440.86Mnot reported separatelynot reported separately90.6%−$237.17M
2022$380.59Mnot reported separatelynot reported separately84.4%−$222.55M
2023$462.28Mnot reported separatelynot reported separately46.9%−$343.4M
2024$376.65Mnot reported separatelynot reported separately34.2%−$22.13M
2025$280.73Mnot reported separatelynot reported separately23.1%$12.19M

The equity ratio divides total equity, including non-controlling interests, by total assets. Net debt is debt minus cash and short-term investments; a negative figure means cash exceeds debt.

Equity and debt

What the company owns and owes

  • Cash & equivalents
  • Equity
  • Debt
Figures as a table
YearCash & equivalentsEquityDebtDebt / Equity
2010$0$0$00
2011$23.33M−$131.96M$00
2012$43.76M$43.93M$00
2013$101.48M$110.47M$00
2014$90.76M$148.65M$200K0
2015$145.21M$236.16M$598K0
2016$210.08M$269.94M$531K0
2017$223.67M$301.68M$458K0
2018$308.73M$393.68M$293K0
2019$335.24M$462.49M$200K0
2020$386.65M$455.58M$9.58M0.02
2021$244M$399.43M$6.84M0.02
2022$249.23M$321.33M$26.69M0.08
2023$369.91M$216.74M$26.51M0.12
2024$248.19M$128.81M$226.06M1.75
2025$188.86M$64.72M$201.06M3.11

Data status and sources

Score
Daily value of 13 Nov 2026, recalculated nightly
Price
Closing price of 12 Nov 2026
Latest annual report
Fiscal year 2025, period end 30 Sep 2025
Source
Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.

Mandatory disclosures for this rating

  • ; time horizon around 12 months
  • Rated Weak, published since 7 Nov 2026 (in the score history since 31 Aug 2020)
  • End-of-day prices, metrics cached for up to 24 hours
  • Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
  • Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
  • Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.

MEQIRI counts visits without cookies. With your consent we remember for 90 days where you came from, also in your account, count page changes and time on page, recognise your next visit and load the Meta Pixel, which measures our advertising. You can withdraw your consent at any time under Cookie settings. Privacy